Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 36,056 | 41,870 | 61,333 | 133,583 | 167,347 |
| Marketable Securities | 243,012 | 273,305 | 374,894 | 482,327 | 315,569 |
| Receivables | 3,539 | 1,826 | 38,480 | 8,676 | 5,515 |
| TOTAL | $291,909 | $331,540 | $502,074 | $633,412 | $494,323 |
| Non-Current Assets | |||||
| PPE Net | 64,384 | 96,836 | 110,020 | 91,529 | 32,308 |
| Investments And Advances | 27,657 | 980 | 4,942 | 100,664 | 0 |
| Other Non-Current Assets | 56,744 | 76,861 | 88,525 | 95,850 | 95,826 |
| TOTAL | $148,785 | $174,677 | $203,487 | $288,043 | $128,134 |
| Total Assets | $440,694 | $506,217 | $705,561 | $921,455 | $622,457 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,365 | 4,719 | 8,265 | 8,612 | 6,283 |
| Accrued Expenses | 21,348 | 27,514 | 53,932 | 42,412 | 15,564 |
| Other current liabilities | N/A | N/A | 4,000 | 3,200 | 39,218 |
| TOTAL | $38,522 | $39,094 | $114,051 | $81,284 | $85,564 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 393 | 685 | 42,226 | 21,483 | 21,144 |
| Other Non-Current Liabilities | 83,446 | 98,706 | 107,571 | 134,209 | 106,427 |
| TOTAL | $83,446 | $98,706 | $107,571 | $161,333 | $152,448 |
| Total Liabilities | $121,968 | $137,800 | $221,622 | $242,617 | $238,012 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 114,597 | 99,238 | 98,162 | 96,428 | 93,783 |
| Common Shares | 114 | 99 | 97 | 96 | 88 |
| Retained earnings | -1,397,994 | -1,211,732 | -1,050,804 | -769,083 | -556,932 |
| Other shareholders' equity | 271 | 18 | -1,851 | -759 | 73 |
| TOTAL | $318,726 | $368,417 | $483,939 | $678,838 | $384,445 |
| Total Liabilities And Equity | $440,694 | $506,217 | $705,561 | $921,455 | $622,457 |